Brief: Eris Lifesciences Announces Strategic Partnership With Natco Pharma For Semaglutide Launch In India
24/02/2026 06:45
Feb 24 (Reuters) - Eris Lifesciences Ltd ERIS.NS: ANNOUNCES STRATEGIC PARTNERSHIP WITH NATCO PHARMA FOR SEMAGLUTIDE LAUNCH IN INDIA Further company coverage: ERIS.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Natco Pharma
See all newsBrief: Natco Pharma Launches Carboplatin Injection In Us With Teyro Labs
India's Natco Pharma jumps after launching ovarian cancer drug in US
Brief: Natco Pharma Announces Launch Of Carboplatin Injection In The U.S. Market
Brief: Natco Pharma To Increase Its Investment In Egenesis To $16.70 Million
Brief: Natco Pharma Approves Rights Issue Up To 12.79 Billion Rupees